Generated October 23, 2026 at 8:32 PM ET
· Covers October 23 trading day
· 9 of 212 ready 8-Ks selected
· AI-assisted overview
The day's highest-materiality filings were led by LKQ's preliminary third-quarter results, which included a net loss tied to a $111 million non-cash impairment and the replacement of CEO Jude with Abbate. Three deals were disclosed: Bolt Biotherapeutics' reverse merger with Prana alongside a $120 million PIPE, Red Cat's EUR 39-per-share cash offer for Steyr Motors, and Unusual Machines' completed acquisition of Upgrade Energy for stock, cash and a potential earn-out. A separate cluster of filings involved exchange listing standards, with Akebia Therapeutics receiving a Nasdaq bid-price deficiency letter, Dragonfly Energy obtaining an extension to Dec. 31 to cure a stockholders' deficit, and Stem reporting NYSE non-compliance on market capitalization and stockholders' equity. Outside those groups, Circle8's Lyneer unit disclosed PEO and lender default notices with a planned UCC asset sale, and Phathom Pharmaceuticals reported litigation challenging FDA's grant of VOQUEZNA exclusivity.
leadership
negative
materiality 0.90
October 23, 2026, 8:06 AM ET
LKQ prelim Q3: revenue $3.32B, adj EPS $0.47-$0.53, net loss on $111M impairment; CEO Jude out, Abbate in
- Q3 revenue $3.32B vs $3.50B a year ago; parts and services organic revenue declined 5.4%.
- Net loss $16M-$32M including $111M non-cash impairment vs $178M net income in Q3 2025; diluted LPS $0.06-$0.12, adjusted EPS $0.47-$0.53 vs $0.84.
- Europe organic revenue -9.8% and segment EBITDA margin 4.1%-5.1% vs 10.0%, blamed on German ERP implementation disruption and UK/Benelux volume declines.
AKBA
Akebia Therapeutics, Inc.
regulatory
negative
materiality 0.75
October 23, 2026, 4:06 PM ET
Akebia gets Nasdaq deficiency letter as stock closes below $1.00 for 30 straight days
- Nasdaq Listing Qualifications notified Akebia on October 21, 2026 that its bid price closed under $1.00 for 30 consecutive business days, breaching Rule 5550(a)(2).
- Akebia has until April 19, 2027 (180 calendar days) to regain compliance by holding a closing bid of at least $1.00 for 10 straight business days.
- If it fails, Akebia could get a second 180-day period by meeting market-value and other initial listing standards and signaling a reverse split if needed.
BOLT
Bolt Biotherapeutics, Inc.
M&A
positive
materiality 0.90
October 23, 2026, 10:31 AM ET
Bolt Biotherapeutics acquires Prana in reverse merger; raises $120M PIPE, Prana holders to own 51.7% post-financing
- Bolt acquired Prana on Oct. 23, 2026; Prana holders received 430,746 BOLT shares plus 16,360.929 Series D preferred shares convertible into 1,000 common each.
- Pre-transaction Bolt holders fall to ~11.8% pre-financing and ~6.9% post-financing; Prana holders ~88.2% then ~51.7%; PIPE investors ~41.4%.
- $120M PIPE sale of 13,995.311 Series D preferred shares plus warrants for 50% more, expected to close Oct. 26, 2026; full warrant exercise would add ~$60M gross.
RCAT
Red Cat Holdings, Inc.
M&A
positive
materiality 0.78
October 23, 2026, 4:05 PM ET
Red Cat launches EUR 39/share cash offer for Steyr Motors, 28.9% premium to Oct 16 close
- Offer of EUR 39.00 in cash per share for all 5,251,261 Steyr Motors shares, implying roughly EUR 205M equity value; acceptance runs to Dec 18, 2026, 5:00 p.m. CET.
- Price is a 28.9% premium to the Oct 16, 2026 close, 27.3% to the 30-day VWAP and 55.8% to the 52-week low.
- Anchor shareholder B&C Holding Österreich GmbH, about 15% of share capital, signed an irrevocable tender undertaking; Steyr's Executive and Supervisory Boards support the deal.
DFLI
Dragonfly Energy Holdings Corp.
regulatory
negative
materiality 0.72
October 23, 2026, 4:30 PM ET
Dragonfly Energy wins Nasdaq extension to Dec 31 to cure $184,000 stockholders' deficit
- Nasdaq Staff granted an extension through December 31, 2026 to regain compliance with the $2.5M minimum stockholders' equity rule, Listing Rule 5550(b)(1).
- Company reported a stockholders' deficit of $(184,000) at June 30, 2026 and failed the alternatives: $35M market value of listed securities or $500K net income.
- Dragonfly submitted its compliance plan to Nasdaq on October 5, 2026; the Staff notified the company of the extension on October 22, 2026.
regulatory
negative
materiality 0.72
October 23, 2026, 4:07 PM ET
Stem gets NYSE non-compliance letter on sub-$50M market cap and stockholders' equity
- Stem notified NYSE on Oct 19, 2026 that it fails Section 802.01B: 30-trading-day average market cap and stockholders' equity must each be at least $50M.
- NYSE sent the non-compliance letter Oct 20, 2026; Stem must submit a business plan within 45 days showing how it will regain compliance within 18 months.
- Plan must set specific quarterly milestones; NYSE will rule on the plan within 45 days and monitor quarterly if accepted.
UMAC
Unusual Machines, Inc.
M&A
positive
materiality 0.72
October 23, 2026, 4:14 PM ET
Unusual Machines closes Upgrade Energy buy: $25M stock, $1M cash, up to $52M with earn-out
- Issued Matthew Barnard 1,792,012 UMAC shares valued at ~$25.0M ($13.9508/share) plus $1.0M cash at closing, funded from cash on hand.
- Earn-out of up to $26.0M cash if Upgrade Energy revenue exceeds $10.0M in the first calculation period; total consideration capped at $52.0M.
- Barnard named CEO of Upgrade Energy under a two-year employment deal: $300,000 base salary, six months' severance on qualifying termination.
PHAT
Phathom Pharmaceuticals, Inc.
litigation
negative
materiality 0.65
October 23, 2026, 5:00 PM ET
BDR sues FDA over VOQUEZNA NCE exclusivity; Phathom defends 10-year term to May 2032
- BDR Pharmaceuticals International Pvt. Ltd. sued FDA and related Federal Defendants in the U.S. District Court for the District of Columbia over an ANDA referencing Phathom's VOQUEZNA NDA.
- BDR alleges FDA improperly applied the GAIN Act to extend Phathom's New Chemical Entity exclusivity for VOQUEZNA (vonoprazan fumarate) tablets.
- Phathom says FDA correctly recognized 10 years of NCE exclusivity through May 3, 2032 in its June 6, 2025 grant of Phathom's December 11, 2024 Citizen Petition.
ATLN
ATLANTIC INTERNATIONAL CORP.
debt
negative
materiality 0.90
October 23, 2026, 5:00 PM ET
Circle8's Lyneer unit gets PEO and SPP default notices; lender SLR plans UCC asset sale
- Lyneer Staffing Solutions received a default notice from professional employer organization Employers Personnel, LLC over alleged payment-obligation defaults; Lyneer is negotiating a resolution.
- SPP Credit Advisors sent Oct 14, 2026 default notices covering the April 29, 2025 Amended and Restated Loan Agreement and June 18, 2024 Bridge Loan; SPP and Agent granted no waiver.
- North Mill Capital d/b/a SLR Business Credit, Lyneer's senior secured lender, intends UCC Article 9 private sales of substantially all Lyneer assets on or after Oct 27, 2026.